ArticleScientific reports2021
Understanding protection from SARS-CoV-2 using metabolomics.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Virgin coconut oil (VCO) supplementation relieves symptoms and inflammation among COVID-19 positive adults: a single-blind randomized trial.Journal of nutritional science · 2024Trial
- Effects of Probiotics and Vitamin D Deficiency Correction on Clinical, Inflammatory, Metabolic, and Microbiota Profiles in Older Adults with Oral Lichen Planus: A Multi-Omics Study.International journal of molecular sciences · 2026Article
- Benchtop NMR as a clinical tool for acute respiratory illness: metabolic signatures associated with disease severity.Respiratory research · 2026Article
- Exploratory comparison of PASC and SARS-CoV-2 infection through metabolomics and lipidomics in early pandemic and Omicron-era.Biochemistry and biophysics reports · 2026Article
- Special Issue: Molecular Research and Insights into COVID-19: 2nd Edition.International journal of molecular sciences · 2025Article
- Higher Serum Monolaurin Is Associated with a Lower Risk of COVID-19: Results from a Prospective Observational Cohort Study.International journal of molecular sciences · 2025Observational
- Multiomics approach identifies dysregulated lipidomic and proteomic networks in Parkinson's disease patients mutated in TMEM175.NPJ Parkinson's disease · 2025Article
- Novel COVID-19 biomarkers identified through multi-omics data analysis: N-acetyl-4-O-acetylneuraminic acid, N-acetyl-L-alanine, N-acetyltriptophan, palmitoylcarnitine, and glycerol 1-myristate.Internal and emergency medicine · 2024Article
- Modifications of Blood Molecular Components after Treatment with Low Ozone Concentrations.International journal of molecular sciences · 2023Article
- Understanding virus-host interactions in tissues.Nature microbiology · 2023Review
- Phenylalanine metabolism and tetrahydrobiopterin bio-availability in COVID-19 and HIV.Heliyon · 2023Article
- Comprehensive Two-Dimensional Gas Chromatography as a Bioanalytical Platform for Drug Discovery and Analysis.Pharmaceutics · 2023Review
- Baseline Plasma Osteopontin Protein Elevation Predicts Adverse Outcomes in Hospitalized COVID-19 Patients.Viruses · 2023Observational
- Protective Barriers Provided by the Epidermis.International journal of molecular sciences · 2023Review
- Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19.Frontiers in molecular biosciences · 2023Review
- Article
- Non-Invasive Paleo-Metabolomics and Paleo-Proteomics Analyses Reveal the Complex Funerary Treatment of the Early 18th Dynasty Dignitary NEBIRI (QV30).Molecules (Basel, Switzerland) · 2022Article
- Precision Medicine Approaches with Metabolomics and Artificial Intelligence.International journal of molecular sciences · 2022Review
- An integrated analysis and comparison of serum, saliva and sebum for COVID-19 metabolomics.Scientific reports · 2022Article
- Prognostic Markers in Hospitalized COVID-19 Patients: The Role of IP-10 and C-Reactive Protein.Disease markers · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic is still raging in most countries. Although the recent mass vaccination campaign has opened a new chapter in the battle against SARS-CoV-2, the world is still far from herd immunity. There is an urgent need to identify healthy people at high risk of contracting COVID-19, as well as supplements and nutraceuticals that can reduce the risk of infection or mitigate symptoms. In the present study, a metabolic phenotype that could protect individuals from SARS-CoV-2 infection or predispose them to developing COVID-19 was investigated. Untargeted metabolomics was performed on serum samples collected from 51 healthcare workers who were in good health at the beginning of the COVID-19 outbreak in Italy, and who were later exposed to the same risk of developing COVID-19. Half of them developed COVID-19 within three weeks of the blood collection. Our results demonstrate the presence of a specific signature associated with protection from SARS-CoV-2. Circulating monolaurin, which has well-known antiviral and antibacterial properties, was higher in protected subjects, suggesting a potential defensive role against SARS-CoV-2 infection; thus, dietary supplements could boost the immune system against this infection. In addition, our data demonstrate that people with higher levels of cholesterol are at higher risk of developing COVID-19. The present study demonstrates that metabolomics can be of great help for developing personalized medicine and for supporting public healthcare strategies. Studies with larger cohorts of subjects are necessary to confirm our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.